eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple myeloma |
| Symptom | C0040038|thromboembolism |
| Sentences | 14 |
| PubMedID- 23014188 | Purpose of review: this review summarizes the current knowledge of the epidemiology, prophylaxis, and treatment of venous thromboembolism (vte) in patients with lymphoma, multiple myeloma or acute leukemia. |
| PubMedID- 21255254 | Introduction: the incidence of venous thromboembolism (vte) in patients with multiple myeloma (mm) treated with thalidomide- and lenalidomide-based regimens is high. |
| PubMedID- 21282540 | In this randomized, open-label, multicenter trial, we compared aspirin (asa) or fixed low-dose warfarin (war) versus low molecular weight heparin (lmwh) for preventing thromboembolism in patients with myeloma treated with thalidomide-based regimens. |
| PubMedID- 20385482 | Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. |
| PubMedID- 25632017 | This study aims to determine the incidence of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory drug therapy in the ambulatory setting at uc health and to investigate adherence with guidelines developed by the national comprehensive cancer network for venous thromboembolism prevention in this patient population. |
| PubMedID- 23903204 | Melisse, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. |
| PubMedID- 26432650 | This study focused on the clinical outcomes in multiple myeloma (mm) patients with venous thromboembolism (vte) who received low-molecular-weight heparin (dalteparin) therapy. |
| PubMedID- 21859556 | Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. |
| PubMedID- 22511493 | We found multiple myeloma patients with venous thromboembolism to have a higher mortality at 1-, 5-, and 10-years of follow up compared with those without, with hazard ratios of 2.9 (95% confidence interval (ci) 2.4-3.5), 1.6 (95% ci: 1.5-1.8), and 1.6 (95% ci: 1.4-1.7), respectively. |
| PubMedID- 20874693 | The background rate of thromboembolism is 4-11% in patients with multiple myeloma, which increases to 15-20% in patients who received intensive treatment with thalidomide. |
| PubMedID- 19901114 | Purpose we conducted a retrospective analysis of the survival effect of venous thromboembolism (vte) development in patients with multiple myeloma (mm). |
| PubMedID- 21720994 | Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. |
| PubMedID- 26177588 | Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide. |
| PubMedID- 24599441 | Venous thromboembolism in multiple myeloma. |
Page: 1